evoke pharma is a biotechnology company located in 505 lomas santa fe dr, solana beach, california, united states.
Company profile
Ticker
EVOK
Exchange
Website
CEO
David Gonyer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
208447886
EVOK stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
10 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
PRE 14A
Preliminary proxy
29 Mar 24
424B3
Prospectus supplement
25 Mar 24
8-K
Entry into a Material Definitive Agreement
25 Mar 24
8-K
Departure of Directors or Certain Officers
21 Mar 24
8-K
Other Events
18 Mar 24
POS EX
Additional exhibits for listing
14 Mar 24
424B3
Prospectus supplement
14 Mar 24
Transcripts
EVOK
Earnings call transcript
2023 Q4
14 Mar 24
EVOK
Earnings call transcript
2022 Q4
21 Mar 23
EVOK
Earnings call transcript
2022 Q3
10 Nov 22
EVOK
Earnings call transcript
2022 Q2
10 Aug 22
EVOK
Earnings call transcript
2022 Q1
10 May 22
EVOK
Earnings call transcript
2021 Q4
9 Mar 22
EVOK
Earnings call transcript
2021 Q3
11 Nov 21
EVOK
Earnings call transcript
2021 Q2
13 Aug 21
EVOK
Earnings call transcript
2021 Q1
13 May 21
EVOK
Earnings call transcript
2020 Q4
12 Mar 21
Latest ownership filings
SC 13G
LYTTON LAURENCE W
13 Mar 24
SC 13G
Bleichroeder LP
11 Mar 24
SC 13G
Altium Capital Management LP
20 Feb 24
SC 13G
HIRSCHMAN ORIN
13 Feb 24
4
KENNETH J WIDDER
11 May 23
4
VICKIE S REED
11 May 23
4
Malcolm R Hill
11 May 23
4
CAM L GARNER
11 May 23
4
Todd C Brady
11 May 23
4
David A Gonyer
10 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.96 mm | 5.96 mm | 5.96 mm | 5.96 mm | 5.96 mm | 5.96 mm |
Cash burn (monthly) | 347.20 k | 532.10 k | 534.48 k | 604.40 k | 347.20 k | 532.10 k |
Cash used (since last report) | 2.39 mm | 3.67 mm | 3.68 mm | 4.16 mm | 2.39 mm | 3.67 mm |
Cash remaining | 3.57 mm | 2.30 mm | 2.28 mm | 1.80 mm | 3.57 mm | 2.30 mm |
Runway (months of cash) | 10.3 | 4.3 | 4.3 | 3.0 | 10.3 | 4.3 |
Institutional ownership, Q2 2023
20.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 1 |
Closed positions | 3 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 100.14 mm |
Total shares | 1.76 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Hirschman Orin | 1.70 mm | $2.76 mm |
Vanguard | 29.85 k | $49.25 mm |
Geode Capital Management | 20.89 k | $34.27 mm |
Tower Research Capital | 5.58 k | $9.21 mm |
BLK Blackrock | 1.47 k | $2.43 mm |
UBS UBS Group AG - Registered Shares | 1.11 k | $1.83 mm |
GWM Advisors | 208.00 | $343.00 k |
Concord Wealth Partners | 31.00 | $51.00 k |
RY Royal Bank Of Canada | 28.00 | $0.00 |
CWM | 16.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 May 23 | Todd C Brady | Stock Option Common Stock | Grant | Acquire A | No | No | 2.12 | 14,625 | 31.01 k | 14,625 |
10 May 23 | Garner Cam L | Stock Option Common Stock | Grant | Acquire A | No | No | 2.12 | 17,750 | 37.63 k | 17,750 |
10 May 23 | Hill Malcolm R | Stock Option Common Stock | Grant | Acquire A | No | No | 2.12 | 14,625 | 31.01 k | 14,625 |
10 May 23 | Vickie S Reed | Stock Option Common Stock | Grant | Acquire A | No | No | 2.12 | 15,000 | 31.80 k | 15,000 |
10 May 23 | Widder Kenneth J | Stock Option Common Stock | Grant | Acquire A | No | No | 2.12 | 14,250 | 30.21 k | 14,250 |
News
Evoke Pharma Announces Senior Leadership Transition With Promotion Of Matthew J. D'Onofrio To Chief Executive Officer, As Of March 31, 2024
21 Mar 24
Recap: Evoke Pharma Q4 Earnings
14 Mar 24
Evoke Pharma Q4 2023 GAAP EPS $(0.59) Misses $(0.50) Estimate, Sales $1.676M Beat $1.632M Estimate
14 Mar 24
Earnings Scheduled For March 14, 2024
14 Mar 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
13 Mar 24
Press releases
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
17 Apr 24
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer
21 Mar 24
Evoke Pharma Announces Closing of $7.5 Million Public Offering
14 Feb 24
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
9 Feb 24